Comparative Pharmacology
Head-to-head clinical analysis: NAQUIVAL versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAQUIVAL versus TEVETEN HCT.
NAQUIVAL vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NAQUIVAL (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing electrolyte reabsorption and increasing urine output, thereby lowering blood pressure and reducing edema.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Adults: 0.1 mg/kg IV bolus, then 0.1 mg/kg/hour continuous IV infusion, titrated to clinical response. Maximum 0.5 mg/kg/hour.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Terminal elimination half-life: 14-16 hours (healthy adults). Extended to 26-35 hours in heart failure or hepatic cirrhosis due to reduced clearance.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Renal: 50-60% as unchanged drug; fecal: <10% (biliary); remainder as metabolites (80% renal, 10% fecal).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category C
Category C
Thiazide Diuretic Combination
ARB + Thiazide Diuretic Combination